Insider · CIK 0001692444
Paula Soteropoulos
Files at DNTH (Dianthus Therapeutics, Inc. /DE/), RLYB (Rallybio Corp). First filing Mar 26, 2026, latest May 11, 2026.
Paula Soteropoulos files SEC Form 4 as director at DNTH (Dianthus Therapeutics, Inc. /DE/), and also at RLYB (Rallybio Corp). Since Mar 26, 2026, Paula Soteropoulos has reported 0 open-market buys worth $0 and 3 open-market sells worth $2.3M, the latest filed on May 11, 2026.
A track record needs three past buys with six months of prices behind them; Paula Soteropoulos has 0, so none is measured yet.
The newest scored trade: sold $51k of DNTH on May 8, 2026, filed May 11, 2026, scored 7 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 3 sells worth $2.3M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
DNTH: Dianthus Therapeutics, Inc. /DE/
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 7Weak | Dianthus Therapeutics, Inc. /DE/ | $51k 599 shares | -100% | +414% from low-9% from high | |
| 15Weak | Dianthus Therapeutics, Inc. /DE/ | $48k 599 shares | -100% | +465% from low-3% from high | |
| 40Moderate | Dianthus Therapeutics, Inc. /DE/ | $2.2M 27,594 shares | -100% | +429% from low-10% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 31, 2026 | DNTH Dianthus Therapeutics, Inc. | 1,198 0.00% of outstanding | $95k | Mar 31, 2026 | $2.2M |
| Mar 24, 2026 | DNTH DIANTHUS THERAPEUTICS, INC. | 27,594 0.06% of outstanding | $2.2M | Mar 24, 2026 | none |
Transactions
Every row this insider has filed, 12 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 21, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | AGrant or award Stock Option (Right to Buy)derivative | +6,090 | $0.00 | $0 | 6,090 | May 22, 2026 |
| May 8, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +599 | $8.44 | $5,056 | 599 | May 11, 2026 |
| May 8, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -599 | $85.47 | $51k | 0 | May 11, 2026 |
| May 8, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -599 | $0.00 | $0 | 0 | May 11, 2026 |
| Mar 31, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +599 | $8.44 | $5,056 | 599 | Apr 1, 2026 |
| Mar 31, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -599 | $80.11 | $48k | 0 | Apr 1, 2026 |
| Mar 31, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -599 | $0.00 | $0 | 599 | Apr 1, 2026 |
| Mar 24, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +27,594 | $8.44 | $233k | 27,594 | Mar 26, 2026 |
| Mar 24, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -27,594 | $78.05 | $2.2M | 0 | Mar 26, 2026 |
| Mar 24, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -27,594 | $0.00 | $0 | 1,198 | Mar 26, 2026 |
| May 22, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | AGrant or award Stock Option (Right to Buy)derivative | +12,500 | $0.00 | $0 | 12,500 | May 22, 2025 |
| May 13, 2025 | RLYB Rallybio Corp | AGrant or award Option (Right to Buy)derivative | +28,500 | $0.00 | $0 | 28,500 | May 15, 2025 |
Questions about Paula Soteropoulos
Answered from the filings on this page, as of the latest one.
Is Paula Soteropoulos buying or selling?
In the last 12 months Paula Soteropoulos reported 0 open-market buys worth $0 and 3 open-market sells worth $2.3M on SEC Form 4; the latest was sold $51k of DNTH on May 8, 2026. Grants, option exercises and tax withholding are not counted.
How did Paula Soteropoulos's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Paula Soteropoulos has 0.
Where does Paula Soteropoulos file Form 4?
Paula Soteropoulos has filed Form 4 at DNTH (Dianthus Therapeutics, Inc. /DE/); RLYB (Rallybio Corp). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.